[Skip to Content]
Visit us on Facebook Visit us on FacebookVisit us on Twitter Visit us on TwitterVisit our RSS Feed View our RSS Feed
Blogadillo June 3rd, 2020
CategoriesCategoriesCategories Contact UsContact Us ArchivesArchives Region/OfficeRegion SearchSearch

Mar

27

Date prong graphic

The Ebola Vaccine: A Race Against Time

Posted by on March 27th, 2020 Posted in: Blog, Disaster, Public Health, Research


In 1976, near the Ebola River in what is now the Democratic Republic of Congo, the disease known as Ebola was first described. For years afterward, scientists fought a largely fruitless uphill battle toward development of an effective and sustainable vaccine for this disease. After sporadically plaguing parts of Africa for decades, a 2014 widespread outbreak of Ebola sent shockwaves through not only West Africa, but the entire world, finally demanding the attention and scientific research support that it had always so desperately needed. The clinical trials and approval process for the rVSV-ZEBOV vaccine, known as Ervebo, were a whirlwind, commonly regarded as a scientific and logistical miracle; however, the road leading to these advancements was littered with seemingly insurmountable obstacles. 

Electron microscopic image of the 1976 isolate of Ebola virus.  Image by CDC

A promising Ebola vaccine backbone was first seriously discussed in the early 1990s – so what took so long to get it developed and approved? It was only through the dogged determination of a few scientists and a laboratory mishap that the vaccine status arrived where it is today.

Barriers on this long road were many. The World Health Organization (WHO) turned down multiple vaccine proposals. Funding was scarce and scant due to lack of interest in working on Ebola prevention and eradication; the pharmaceutical industry brazenly questioned the purpose of pouring resources into research which would largely benefit only poor and rural African communities. Scientists frequently found themselves having to defend their research against persistent scrutiny. Health infrastructure in affected nations was weak. Other more visible widespread health scares such as the SARS virus garnered more attention and therefore more research funding. Urgency simply did not exist. 

In 2009, a German scientist accidentally pricked her finger with a needle containing the Ebola virus, initiating a swift response which would drastically change the course of vaccine development. The unnamed scientist was almost immediately given the vaccine, which was not human grade and completely untested on humans. After several days of quarantine, she was found to be uninfected with Ebola and, more importantly, had not suffered any adverse side effects to the drug. Funding for the Ebola vaccine was eventually secured, but only to the tune of 2 million dollars, small by scientific research standards, from a company focused on biomedical terrorism. The lab in Winnipeg where research was being conducted finally found a development partner, but one who was not specifically interested in the work that was being done, but rather focused on growing its portfolio assets. The lab took the support wherever they could get it.

Then began the now-infamous Ebola outbreak, which likely began in Guinea in 2013 when patients with the disease were misdiagnosed and healthcare professionals contracted the illness from them; it was only then that Ebola was formally diagnosed. In 2014, it began to spread like wildfire in unparalleled ways into urban areas and eventually into other countries. It was declared a global health emergency by the WHO in August 2014.

It was during this time that scientists worked at a fever pitch to accelerate the development of the vaccine they so fervently believed in, often navigating murky ethical waters. Even after the drug was found to be clinically effective, the Food and Drug Administration in the United States expressed no interest in it. Still, researchers pressed on. Out of sheer necessity, complete clinical trials were eventually conducted, taking (from start to finish) fewer than 12 months, an unprecedented timeline in the field. Even after apparent vaccine success, there was substantial backlash doubting whether its efficacy was adequately proven.

Since another outbreak, this time in 2018 in the Democratic Republic of Congo, healthcare workers in the area have agreed to administer the vaccine via a “compassionate care” model. Since then, around 260,000 people have been successfully vaccinated.

At long last, the end of 2019 brought the news that scientists had been waiting for; In November, the European Commission approved Ervebo and in December, the U.S. Food and Drug Administration (FDA) did the same.

Read the full remarkable story here. To learn more about Ebola’s chronology, visit this page maintained by the Centers for Disease Control (CDC).

Remember to follow us on Facebook and Twitter!

 

Image of the author ABOUT E. Bailey Sterling
I am a Digital Communications Specialist contracted with the NNLM SCR and presently a graduate student pursuing an MS in Information Science specializing in Health Informatics from the University of North Texas (GMG!). I'm an analog gamer, writer, and lifelong learner living in DFW. If you have anything you'd like to see featured on the NNLM SCR blog or social channels, please contact me. I'd love to hear more about what's happening at your library!

Email author View all posts by
Funded under cooperative agreement number UG4LM012345 with the University of North Texas Health Science Center - Gibson D. Lewis Library, and awarded by the DHHS, NIH, National Library of Medicine.

NNLM and NATIONAL NETWORK OF LIBRARIES OF MEDICINE are service marks of the US Department of Health and Human Services | Copyright | Download PDF Reader